PSA, PSAD Less Predictive of Aggressive PCa in Black Men
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
Prostate And Other Male Cancers
5-Year PCa-Specific Mortality Declined With Increased PSA Testing
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Black Patients May Be Adversely Affected by Less PSA Screening
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
Fewer Prostate Biopsies After USPSTF Limited PSA Screening
Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.
New Prostate Cancer Screening Algorithm Proposed
A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.
Radiographic Progression of mCRPC Without Rising PSA
In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.
PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA
After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.
Digital Rectal Examination, PSA Testing Rates Declining
Decreases in use of screening following USPSTF recommendations against routine PSA screening.
Latest Assays Can Improve Prostate Cancer Workup
Clinicians now have tools for improving prostate cancer screening and risk stratification.
PSA of ≥0.4 ng/mL Predicts PCa Progression
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.
Next post in Prostate Cancer
